ClinicalTrials HQ

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Active, not recruiting · NCT04239625 · Registry updated 2026-09-21
Ask about research services

Clinical trials

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Stargardt disease, eye disorder, hereditary disease, macular degeneration, retinal degeneration, retinal disorderActive, not recruitingPhase 22026-09-21NCT04239625

1 results · Page 1 of 1

Organizations

Swipe the table sideways for more columns.

OrganizationsLinked trials
Alkeus Pharmaceuticals, Inc.3

8 results · Page 1 of 1

Research sites

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
Alkeus SiteGainesvilleUnited States2
Alkeus SiteWestburyUnited States2
Alkeus SiteLos AngelesUnited States2
Alkeus SiteIndianapolisUnited States2
Alkeus SitePhoenixUnited States2
Alkeus SiteAuroraUnited States2
Alkeus SiteSilverdaleUnited States2
Alkeus SiteGrand RapidsUnited States1